stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Free cash flow margin
Roivant Sciences Ltd.'s free cash flow margin over the twelve months to 30 June 2026 was −10,901.0%, down 1717.5 percentage points from fiscal 2026 (−9,183.5%). Over the past ten years it has ranged from −9,183.5% (fiscal 2026) to 0.00% (fiscal 2020) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | −9,183.5% | (6,278.30) |
| FY2025 | −2,905.2% | (561.65) |
| FY2024 | −2,343.6% | (946.56) |
| FY2023 | −1,397.0% | (139.60) |
| FY2022 | −1,257.4% | 1,087.40 |
| FY2021 | −2,344.8% | (2,344.80) |
| FY2020 | 0.00% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 113.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 21.9% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 16.1% |
| INCY Incyte Corporation compare | 11.3% |
| BNTX BioNTech SE Sponsored ADR compare | −19.2% |
| INSM Insmed, Inc. compare | −41.3% |
| GMAB Genmab A/S Sponsored ADR compare | −153.6% |
| RVMD Revolution Medicines, Inc. compare | −688.9% |
| ROIV Roivant Sciences Ltd. | −10,901.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement